[Edaily Starin Choi Hee-jae Reporter] The movie "The Odyssey" is a box office hit, having drawn 2 million viewers just six days after its release. Still from the movie “The Odyssey” (Photo courtesy of Universal Pictures) According to the Korean Film Council’s integrated computer network on the 10th, “The Odyssey” surpassed 2 million cumulative viewers around 6 a.m. that day. "The Odyssey" topped the weekend box office by drawing 1,333,571 viewers over the three-day weekend from the 7th to the 9th. Since its release on the 5th, "The Odyssey" has held the No. 1 spot at the box office for five consecutive days, surpassing the Marvel blockbuster "Spider-Man: Brand New Day" (Spider-Man 4). The speed at which “Odyssey” reached the 2 million mark is six days faster than that of “The Man Who Lives with the King” (“Wangsa-nam”), a film that drew 16.91 million viewers in South Korea. It is also six days faster than director Christopher Nolan’s previous film, “Oppenheimer.” The film has also been receiving positive reviews from audiences since its release. It maintains a high audience satisfaction rating of 97% on CGV’s Golden Egg Index. As of 4:10 p.m. on the 10th, according to Naver, the rating from actual moviegoers stands at 9.23, while the rating from netizens is 9.02. As of 4:10 p.m., “Odyssey” holds a real-time ticket reservation rate of 63.6%. This figure is higher than the 46.9% reservation rate recorded on opening day. As *The Odyssey* continues its box office run both domestically and internationally, fueled by word of mouth, all eyes are on what new records it will set. “The Odyssey” follows the journey of Odysseus (played by Matt Damon), the hero who led the 10-year Trojan War to victory, as he sets out to return to his wife Penelope (played by Anne Hathaway) and his son Telemachus (played by Tom Holland). The film is currently playing in theaters nationwide.
Global asset management firms are offering comprehensive portfolios—including private assets—targeted at high-net-worth individuals and wealth management (WM) clients. Previously, portfolios were prim…
SK hynix has drawn a clear line regarding reports that it is pursuing the sale of its stake in its Chongqing, China, plant, stating, “Nothing has been finalized.” This is the company’s response to a r…
Medy-Tox Inc.(086900)Medytox continued its revenue growth in the second quarter of this year, driven by expanded overseas sales of botulinum toxin and dermal fillers, as well as the successful market …